During the corresponding time, Globus Medical Inc recorded a revenue increase by 5.94 % year on year, sequentially revenue grew by 3.92 %. While revenue at the Globus Medical Inc 's corporate clients
Globus Medical Inc's Comment on Sales, Marketing and Customers
The company operates in the musculoskeletal market, providing products for the treatment of musculoskeletal disorders. Its portfolio includes implantable devices, biologics, surgical instruments, spinal cord stimulation therapy, and neuromonitoring services. The products are used in spinal, orthopedic, and neurosurgical procedures to address conditions such as degenerative and congenital disorders, deformities, tumors, and traumatic injuries. The company offers solutions for both conservative therapies and surgical interventions, including instrumented and non-instrumented treatments. Its product range supports open and minimally invasive surgical techniques and includes traditional fusion implants as well as expandable options for interbody fusion, corpectomy, and interspinous fixation. The company provides customized treatment options based on patient anatomy and surgeon preference, supported by a trained sales force and corporate account management.
Globus Medical Reports First Quarter 2025 Results AUDUBON, Pa. May 08, 2025 Globus Medical, Inc. (NYSE: GMED), a prominent player in the musculoskeletal solutions sector, has announced its financial results for the first quarter of 2025. The company demonstrated resilience amid challenging market conditions as it revealed its performance metrics, including a notable decrease in free cash flow margin.For the quarter ending March 31, 2025, Globus Medical reported a free cash flow margin of 32%, a reduction compared to previous quarters but still above the company’s historical average. This decline, noted to occur in the fourth quarter of the previous fiscal year, positions Globus Medical in a competitive ...
Globus Medical Inc’s Comment on Sales, Marketing and Customers
The company operates in the musculoskeletal market, providing products for the treatment of musculoskeletal disorders. Its portfolio includes implantable devices, biologics, surgical instruments, spinal cord stimulation therapy, and neuromonitoring services. The products are used in spinal, orthopedic, and neurosurgical procedures to address conditions such as degenerative and congenital disorders, deformities, tumors, and traumatic injuries. The company offers solutions for both conservative therapies and surgical interventions, including instrumented and non-instrumented treatments. Its product range supports open and minimally invasive surgical techniques and includes traditional fusion implants as well as expandable options for interbody fusion, corpectomy, and interspinous fixation. The company provides customized treatment options based on patient anatomy and surgeon preference, supported by a trained sales force and corporate account management.
Sources:
Globus Medical Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Globus Medical Inc’s corporate clients.
For your research, we’ve provided 9 tables on Globus Medical Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
189.53 %